AN2 Therapeutics Inc. Focuses on Transformative Medicines for Infectious Diseases

Menlo Park, United States — AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, continues to advance its mission of developing transformational medicines for patients suffering from infectious diseases. The company, which operates globally, is based in Menlo Park, United States, and is listed on the Nasdaq stock exchange.

Company Overview

AN2 Therapeutics specializes in modern biomedical and drug development, aiming to address unmet medical needs in the field of infectious diseases. The company’s innovative approach to drug development is designed to provide significant advancements in treatment options for patients worldwide.

Financial Snapshot

As of May 8, 2025, AN2 Therapeutics’ stock closed at $1.20 on the Nasdaq. The company’s market capitalization stands at $37,320,000 USD. Over the past year, the stock has experienced fluctuations, reaching a 52-week high of $3.07 on July 16, 2024, and a 52-week low of $0.87 on August 8, 2024. The price-to-earnings ratio is currently -0.70882, reflecting the company’s ongoing investment in research and development.

Strategic Focus

AN2 Therapeutics remains committed to its strategic focus on infectious diseases, leveraging cutting-edge technology and research to develop new therapies. The company’s efforts are aimed at addressing critical gaps in the treatment landscape, with the goal of improving patient outcomes and advancing global health.

For more information about AN2 Therapeutics and its operations, visit their website at www.an2therapeutics.com .